Status:
COMPLETED
Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling
Lead Sponsor:
Somaxon Pharmaceuticals
Conditions:
Pathological Gambling
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to determine if nalmefene is safe and effective in the treatment of pathological gambling.
Detailed Description
Randomized, double-blind, placebo-controlled, parallel-group, multi-centered, outpatient study to assess the efficacy, safety and tolerability of two doses of nalmefene in patients with current diagno...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Current diagnosis of pathological gambling as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
Exclusion
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2006
Estimated Enrollment :
233 Patients enrolled
Trial Details
Trial ID
NCT00132119
Start Date
August 1 2005
End Date
August 1 2006
Last Update
May 19 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.